From Yahoo Finance: 2025-05-19 09:28:00

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will acquire 23andMe for $256 million, following 23andMe’s bankruptcy filing in March. REGN plans to take over 23andMe’s Personal Genome Service, Total Health, and Research Services business line, with the deal expected to close by the third quarter of 2025.

The acquisition is pending bankruptcy court and regulatory approvals. REGN’s Co-Founder and Chief Scientific Officer, George D. Yancopoulos, M.D. Ph.D., highlighted REGN’s focus on DNA-driven drug discovery efforts, including treatments for various diseases like cancer and COVID-19.

While REGN shows growth potential, some believe that other AI stocks offer higher returns with less downside risk. For those interested in AI stocks with significant upside potential, consider exploring the report on the cheapest AI stock. No promotional content included.

Read more: Regeneron Pharmaceuticals to Acquire 23andMe for $256M